Abstract
Damage from oxidative stress and mitochondrial dysfunction occur together in many common neurodegenerative diseases. The enzymes that form the mitochondrial α-ketoglutarate-dehydrogenase complex (KGDHC), a key and arguably rate-limiting enzyme system of the tricarboxylic acid cycle, might mediate the interaction of these processes. KGDHC activity is reduced in numerous age-related neurodegenerative diseases and is diminished by oxidative stress. In Alzheimer’s disease (AD), the reduction correlates highly to diminished mental performance. Thus, research has focused on the mechanisms by which select oxidants reduce KGDHC and the consequences of such a reduction. Diminished KGDHC in cells is associated with apoptosis without changes in the mitochondrial membrane potential. Studies of isolated mitochondria and of animal models suggest that a reduction in KGDHC can predispose to damage by other toxins that promote neurodegeneration. Diminished oxidative metabolism can be plausibly linked to pathological features of neurodegenerative diseases (e.g., reduced mental function, the plaques and tangles in AD). Thus, reductions in KGDHC might be central to the pathophysiology of these diseases. Studies of proteins, cells, animal models, and humans suggest that treatments to diminish, or bypass, the reduction in KGDHC might be beneficial in age-related neurodegenerative disorders.
Similar content being viewed by others
References
Atwood C.S., Martins R.N., Smith M.A., and Perry G. (2002) Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 23, 1343–1350.
Planel E., Miyasaka T., Launey T., et al. (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease. J. Neurosci. 24, 2401–2411.
Siesjo B.K. (1978) Brain Energy Metabolism. Wiley, New York.
Butterworth R.F., Kril J.J., and Harper C.G. (1993) Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome. Alcohol Clin. Exp. Res. 17, 1084–1088.
Mosconi L., Sorbi S., Nacmias B., et al. (2004) Age and ApoE genotype interaction in Alzheimer’s disease: an FDG-PET study. Psychiatry Res. 130, 141–151.
Mosconi L., Nacmias B., Sorbi S., et al. (2004) Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 75, 370–376.
Reiman E.M., Chen K., Alexander G.E., et al. (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl. Acad. Sci. USA 101, 284–289.
De Santi S., de Leon M.J., Rusinek H., et al. (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22, 529–539.
Arnaiz E., Jelic V., Almkvist O., et al. (2001) Impaired cerebral glucose metabolism and cognitive functioning predict deteioration in mild cognitive impairment. Neuroreport 12, 851–855.
de Leon M.J., Convit A., Wolf O.T., et al. (2001) Prediction of cognitive decline in normal elderly subjects with 2-2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 98, 10,966–10,971.
Alexander G.E., Chen K., Pietrini P., Rapoport S.I., and Reiman E.M. (2002) Longitudinal PET Evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am. J. Psychiatry 159, 738–745.
Shoghi-Jadid K., Small G.W., Agdeppa E.D., et al. (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24–35.
Craft S., Zallen G., and Baker L.D. (1992) Glucose and memory in mild senile dementia of the Alzheimer type. J. Clin. Exp. Neuropsychol. 14, 253–267.
Niwa K., Kazama K., Younkin S.G., Carlson G.A., and Iadecola C. (2002) Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9, 61–68.
Park L.C., Zhang H., Sheu K.F., et al. (1999) Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia. J. Neurochem. 72, 1948–1958.
Calingasan N.Y., Uchida K., and Gibson G.E. (1999) Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer’s disease. J. Neurochem. 72, 751–756.
Pratico D., Uryu K., Leight S., Trojanoswki J.Q., and Lee V.M. (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21, 4183–4187.
Pratico D., Clark C.M., Liun F., Rokach J., Lee V.Y., and Trojanowski J.Q. (2002) Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59, 972–976.
Yao Y., Zhukareva V., Sung S., et al. (2003) Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 61, 475–478.
Fessel J.P., Hulette C., Powell S., Roberts L.J. 2nd, and Zhang J. (2003) Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson’s disease and with dementia with Lewy body disease. J. Neurochem. 85, 645–650.
Almaas E., Kovacs B., Vicsek T., Oltvai Z.N., and Barabasi A.L. (2004) Global organization of metabolic fluxes in the bacterium Escherichia coli. Nature 427, 839–843.
McCormack J.G. and Denton R.M. (1979) The effects of calcium ions and adenine nucleotides on the activity of pig heart 2-oxoglutarate dehydrogenase complex. Biochem. J. 180, 533–544.
Rutter G.A. (1990) Ca2(+)-binding to citrate cycle dehydrogenases. Int. J. Biochem. 22, 1081–1088.
Jacobson J. and Duchen M.R. (2004) Interplay between mitochondria and cellular calcium signalling. Mol. Cell. Biochem. 256–257, 209–218.
Blass J.P., Sheu R.K., and Gibson G.E. (2000) Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann. NY Acad. Sci. 903, 204–221.
Gibson G.E., Park L.C., Sheu K.F., Blass J.P., and Calingasan N.Y. (2000) The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int. 36, 97–112.
Sheu K.F. and Blass J.P. (1999) The alpha-ketoglutarate dehydrogenase complex. Ann. NY Acad. Sci. 893, 61–78.
Gibson G.E., Sheu K.F., and Blass J.P. (1998) Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 105, 855–870.
Massy V. Lipoyl dehydrogenase. Enzymes 7, 275–306.
Lawlis V.B. and Roche T.E. (1981) Inhibition of bovine kidney alpha-ketoglutarate dehydrogenase complex by reduced nicotinamide adenine dinucleotide in the presence or absence of calcium ion and effect of adenosine 5′-diphosphate on reduced nicotinamide adenine dinucleotide inhibition. Biochemistry 20, 2519–2524.
Bunik V.I. (2003) 2-Oxo acid dehydrogenase complexes in redox regulation: role of the lipoate residues and thioredoxin. Eur. J. Biochem. 270, 1036–1042.
Bunik V.I., Buneeva O.A., Lvova N.B., and Gomazkova V.S. (1989) Structural and functional peculiarities of alpha-ketoglutarate dehydrogenase with non-interacting active sites. Biochem. Int. 18, 561–571.
Bunik V.I., Buneeva O.A., and Gomazkova V.S. (1990) Change in alpha-ketoglutarate dehydrogenase cooperative properties due to dihydrolipoate and NADH. FEBS Lett. 269, 252–254.
Bunik V., Follmann H., and Bisswanger H. (1997) Activation of mitochondrial 2-oxoacid dehydrogenases by thioredoxin. Biol. Chem. 378, 1125–1130.
Bunik V.I. and Sievers C. (2002) Inactivation of the 2-oxo acid dehydrogenase complexes upon generation of intrinsic radical species. Eur. J. Biochem. 269, 5004–5015.
Bunik V., Shoubnikova A., Loeffelhardt S., Bisswanger H., Borbe H.O., and Follmann H. (1995) Using lipoate enantiomers and thioredoxin to study the mechanism of the 2-oxoacid-dependent dihydrolipoate production by the 2-oxoacid dehydrogenase complexes. FEBS Lett. 371, 167–170.
Gourlay L.J., Bhella D., Kelly S.M., Price N.C., and Lindsay J.G. (2003) Structure-function analysis of recombinant substrate protein 22 kDa (SP-22). A mitochondrial 2-CYS peroxiredoxin organized as a decameric toroid. J. Biol. Chem. 278, 32,631–32,637.
Bryk R., Lima C.D., Erdjument-Bromage H., Tempst P., and Nathan C. (2002) Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science 295, 1073–1077.
Starkov A.A. and Fiskum G. (2003) Regulation of brain mitochondrial H2O2 production by membrane potential and NAD(P)H redox state. J. Neurochem. 86, 1101–1107.
Sreider C.M., Grinblat L., and Stoppani A.O. (1992) Reduction of nitrofuran compounds by heart lipoamide dehydrogenase: role of flavin and the reactive disulfide groups. Biochem. Int. 28, 323–334.
Gazaryan I.G., Krasnikov B.F., Ashby G.A., Thorneley R.N., Kristal B.S., and Brown A.M. (2002) Zinc is a potent inhibitor of thiol oxidoreductase activity and stimulates reactive oxygen species production by lipoamide dehydrogenase. J. Biol. Chem. 277, 10,064–10,072.
Matuda S. and Obo F. (1979) Hg2+-stimulated NADH-oxidase activity of Ascaris muscle microsomal lipoamide dehydrogenase. Biochem. Biophys. Res. Commun. 91, 835–841.
Kanamori T., Nishimaki K., Asoh S., Ishibashi Y., Takata I., Kuwabara T., Taira K., et al. (2003) Truncated product of the bifunctional DLST gene involved in biogenesis of the respiratory chain. EMBO J. 22, 2913–2923.
Li K.W., Hornshaw M.P., Van Der Schors R.C., et al. (2004) Proteomics analysis of rat brain postsynaptic density. Implications of the diverse protein functional groups for the integration of synaptic physiology. J. Biol. Chem. 279, 987–1002.
Gibson G.E., Zhang H., Sheu K.F., et al. (1998) Alpha-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation. Ann. Neurol. 44, 676–681.
Gibson G.E., Haroutunian V., Zhang H., et al. (2000) Mitochondrial damage in Alzheimer’s disease varies with apolipoprotein E genotype. Ann. Neurol. 48, 297–303.
Mastrogiacoma F., Lindsay J.G., Bettendorff L., Rice J., and Kish S.J. (1996) Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. Ann. Neurol. 39, 592–598.
Ma Q., Chan P., and Yang J. (2001) [Association between DLST gene polymorphism and Alzheimer’s disease]. Zhonghua Yi Xue Za Zhi 81, 1246–1248.
Sheu K.F., Brown A.M., Kristal B.S., et al. (1999) A DLST genotype associated with reduced risk for Alzheimer’s disease. Neurology 52, 1505–1507.
Sheu K.F., Brown A.M., Haroutunian V., et al. (1999) Modulation by DLST of the genetic risk of Alzheimer’s disease in a very elderly population. Ann. Neurol. 45, 48–53.
Brown A.M., Gordon D., Lee H., Caudy M., Haroutunian V., and Blass J.P. (2004) Substantial linkage disequilibrium across the dihydrolipoyl succinyltransferase gene region without Alzheimer’s disease association. Neurochem. Res. 29, 629–635.
Matsushita S., Arai H., Yuzuriha T., et al. (2001) No association between DLST gene and Alzheimer’s disease or Wernicke-Korsakoff syndrome. Neurobiol. Aging 22, 569–574.
Brown A.M., Gordon D., Lee H., et al. (2004) Association of the dihydrolipoamide dehydrogenase gene with Alzheimer’s disease in an Ashkenazi Jewish Population. Am. J. Med. Genet. 131, 60–66.
Brown A.M., Vrieze F.S.W., Gordon D., et al. (2004) Independent case-control confirmation of association dld with ad. International Alzeimer Meeting, 9:P4–066.
Gibson G.E., Kingsbury A.E., Xu H., et al. (2003) Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson’s disease. Neurochem. Int. 43, 129–135.
Klivenyi P., Starkov A.A., Calingasan N.Y., et al. (2004) Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J. Neurochem. 88, 1352–1360.
Albers D.S., Augood S.J., Park L.C., et al. (2000) Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J. Neurochem. 74, 878–881.
Park L.C., Albers D.S., Xu H., Lindsay J.G., Beal M.F., and Gibson G.E. (2001) Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J. Neurosci. Res. 66, 1028–1034.
Bubber P., Tang J., Haroutunian V., et al. (2004) Mitochondrial enzymes in schizophrenia. Mol. Neurosci. 24, 231–237.
Lucas D.T. and Sweda L.I. (1999) Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase. Proc. Natl. Acad. Sci. USA 96, 6689–6693.
Humphries K.M., Yoo Y., and Szweda L.I. (1998) Inhibition of NADH-linked mitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry 37, 552–557.
Xu H., Jeitner T., Zhang H., and Gibson G.E. (2001) α-Ketoglutarate dehydrogenase and oxidative stress. International Society for Neurochemistry. J. Neurochem. 78S, 132.
Chinopoulos C., Tretter L., and Adam-Vizi V. (1999) Depolarization of in situ mitochondria due to hydrogen peroxide-induced oxidative stress in nerve terminals: inhibition of alphaketoglutarate dehydrogenase. J. Neurochem. 73, 220–228.
Gibson G.E., Zhang H., Sheu K.R., and Park L.C. (2000) Differential alterations in antioxidant capacity in cells from Alzheimer patients. Biochim. Biophys. Acta 1502, 319–329.
Nulton-Persson A.C., Starke D.W., Mieyal J.J., and Szweda L.I. (2003) Reversible inactivation of alpha-ketoglutarate dehydrogenase in response to alterations in the mitochondrial glutathione status. Biochemistry 42, 4235–4242.
Rokutan K., Kawai K., and Asada K. (1987) Inactivation of 2-oxoglutarate dehydrogenase in rat liver mitochondria by its substrate and t-butyl hydroperoxide. J. Biochem. (Tokyo) 101, 415–422.
Cabiscol E., Piulats E., Echave P., Herrero E., and Ros J. (2000) Oxidative stress promotes specific protein damage in Saccharomyces cerevisiae. J. Biol. Chem. 275, 27,393–27,398.
Correa J.G. and Stoppani A.O. (1996) Catecholamines enhance dihydrolipoamide dehydrogenase inactivation by the copper Fenton system. Enzyme protection by copper chelators. Free Radical Res 24, 311–322.
Pocernich C.B. and Butterfield D.A. (2003) Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer’s disease. Neurotox. Res. 5, 515–520.
Moreau R., Heath S.H., Doneanu C.E., Lindsay J.G., and Hagen T.M. (2003) Age-related increase in 4-hydroxynonenal adduction to rat heart alpha-ketoglutarate dehydrogenase does not cause loss of its catalytic activity. Antioxid. Redox Signal. 5, 517–527.
Pruijn F.B., Schoonen W.G., and Joenje H. (1992) Inactivation of mitochondrial metabolism by hyperoxia-induced oxidative stress. Ann. NY Acad. Sci. 663, 453–455.
Schoonen W.G., Wanamarta A.H., van der Klei-van Moorsel J.M., Jakobs C., and Joenje H. (1990) Respiratory failure and stimulation of glycolysis in Chinese hamster ovary cells exposed to normobaric hyperoxia. J. Biol. Chem. 265, 1118–1124.
Kumar M.J., Nicholls D.G., and Andersen J.K. (2003) Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson’s disease. J. Biol. Chem. 278, 46,432–46,439.
Hinerfeld D., Traini M.D., Weinberger R.P., Cochran B., Doctrow S.R., Harry J., et al. (2004) Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J. Neurochem. 88, 657–667.
Gibson G.E., Zhang H., Xu H., Park L.C., and Jeitner T.M. (2002) Oxidative stress increases internal calcium stores and reduces a key mitochondrial enzyme. Biochim. Biophys. Acta 1586, 177–189.
McNaught K.S., Carrupt P.A., Altomare C., et al. (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson’s disease. Biochem. Pharmacol. 56, 921–933.
McNaught K.S., Altomare C., Cellamare S., et al. (1995) Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroreport 6, 1105–1108.
Li H. and Dryhurst G. (2001) Oxidative metabolites of 5-S-cysteinyldopamine inhibits the pyruvate dehydrogenase complex. J. Neural Transm. 108, 1363–1374.
Jiang X.R. and Dryhurst G. (2002) Inhibition of the alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes by a putative aberrant metabolite of serotonin, tryptamine-4,5-dione. Chem. Res. Toxicol. 15, 1242–1247.
Park L.C., Gibson G.E., Bunik V., and Cooper A.J. (1999) Inhibition of select mitochondrial enzymes in PC12 cells exposed to S-(1,1,2,2-tetrafluoroethyl)-l-cysteine. Biochem. Pharmacol. 58, 1557–1565.
Cooper A.J., Sheu K.R., Burke J.R., et al. (1997) Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc. Natl. Acad. Sci. USA 94, 12,604–12,609.
Nghiem H.O., Bettendorff L., and Changeux J.P. (2000) Specific phosphorylation of Torpedo 43K rapsyn by endogenous kinase(s) with thiamine triphosphate as the phosphate donor. FASEB J. 14, 543–554.
Parkhomenko Yu. M., Protasova Z.S., Chernysh I.Yu., and Pkhakadze E.G. (1991) Modulation of acethylcholine synthesis in rat brain synaptosomes by thiamine and its relation to the regulation of the pyruvate dehydrogenase complex activity, in Biochemistry and Physiology of Thiamine Diphosphate Enzymes. Proceedings of the International Meeting on the Function of Thiamine Diphosphate enzymes, Bisswanger H. and Ullrich J., eds., VCH, Weinheim.
Ke Z. and Gibson G.E. (2004) Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism. Neurochem. Int., 45, 361–369.
Sheu K.F., Calingasan N.Y., Lindsay J.G., and Gibson G.E. (1998) Immunochemical characterization of the deficiency of the alpha-ketoglutarate dehydrogenase complex in thiamine-deficient rat brain. J. Neurochem. 70, 1143–1150.
Park L.C., Calingasan N.Y., Uchida K., Zhang H., and Gibson G.E. (2000) Metabolic impairment elicits brain cell type-selective changes in oxidative stress and cell death in culture. J. Neurochem. 74, 114–124.
Gibson G.E. and Blass J.P. (1976) Inhibition of acetylcholine synthesis and of carbohydrate utilization by maple-syrup-urine disease metabolites. J. Neurochem. 26, 1073–1078.
Huang H.M., Zhang H., Xu H., and Gibson G.E. (2003) Inhibition of the alpha-ketoglutarate dehydrogenase complex alters mitochondrial function and cellular calcium regulation. Biochim. Biophys. Acta 1637, 119–126.
Huang H.M., Ou H.C., Xu H., Chen H.L., Fowler C., and Gibson G.E. (2003) Inhibition of alpha-ketoglutarate dehydrogenase complex promotes cytochrome c release from mitochondria, caspase-3 activation, and necrotic cell death. J. Neurosci. Res. 74, 309–317.
Tretter L. and Adam-Vizi V. (2000) Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of α-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J. Neurosci. 20, 8972–8979.
Stavrovskaya I.G., Krasnikov B.F., Lukyanova M., and Kristal, B.S. (2003) Impairment of α-ketoglutarate dehydrogenase activity facilitates the mitochondrial permeability transition. Keystone symposia. Mitochondria.
Guest J.R., Attwood M.M., Machado R.S., Matqi K.Y., Shaw J.E., and Turner S.L. (1997) Enzymological and physiological consequences of restructuring the lipoyl domain content of the pyruvate dehydrogenase complex of Escherichia coli. Microbiology 143(Pt. 2), 457–466.
Dave E., Guest J.R., and Attwood M.M. (1995) Metabolic engineering in Escherichia coli: lowering the lipoyl domain content of the pyruvate dehydrogenase complex adversely affects the growth rate and yield. Microbiology 141(Pt. 8), 1839–1849.
Guest J.R., Ali S.T., Artymu P., Ford G., Green J., and Russsel G.C. (1990) Site directed mutatagenesis of dihydrolipoaminde acetyltransferase and post translational modification of it in lipoyl domains, in Biochemistry and Physiology of Thiamin Diphosphate Enzymes, (Bisswanger, H. and Shellenberger, A., eds.), Chemie, Weinheim, pp. 176–193.
Ekinci F.J., Linsley M.D., and Shea T.B. (2000) Beta-amyloid-induced calcium influx induces apoptosis in culture by oxidative stress rather than tau phosphorylation. Brain Res. Mol. Brain Res. 76, 389–395.
Sponne I., Fifre A., Drouet B., Klein C., et al. (2003) Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J. Biol. Chem. 278, 3437–3445.
Behl C. and Moosmann B. (2002) Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach. Free Radical Biol. Med. 33, 182–191.
Behl C., Davis J.B., Lesley R., and Schubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817–827.
Varadarajan S., Kanski J., Aksenova M., Lauderback C., and Butterfield D.A. (2001) Different mechanisms of oxidative stress and neurotoxicity for alzheimer’s abeta(1–42) and abeta(25–35). J. Am. Chem. Soc. 123, 5625–5631.
Varadarajan S., Yatin S., Aksenova M., and Butterfield D.A. (2000) Alzheimer’s amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184–208.
Olivieri G., Baysang G., Meier F., et al. (2001) N-Acetyl-l-cyseine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J. Neurochem. 76, 224–233.
Huang X., Atwood C.S., Hartshorn M.A., et al. (1999) The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609–7616.
Pereira C., Santos M.S., and Oliveira C. (1999) Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants. Neurobiol. Dis. 6, 209–219.
Shearman M.S., Ragan C.I., and Iversen L.L. (1994) Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA 91, 1470–1474.
Sharpe M.A., Canevari L., Clark J.B., and Casley C. (2001) β-Amyloid inhibits mitohondrial cytochrome oxidase and exacerbates nitric oxide toxicity: implications for Alzheimer’s disease. J. Neurochem. 78S, 91.
Casley C.S., Canevari L., Land J.M., Clark J.B., and Sharpe M.A. (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80, 91–100.
Lustbader J.W., Cirilli M., Lin C., et al. (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science 304, 448–452.
Kaido M., Fujimura H., Soga F., et al. (1996) Alzheimer-type pathology in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neuropathol. (Berl.) 92, 312–318.
Pierrot N., Ghisdal P., Caumont A.S., and Octave J.N. (2004) Intraneuronal amyloidbeta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J. Neurochem. 88, 1140–1150.
Calingasan N.Y., Gandy S.E., Baker H., et al. (1996) Novel neuritic clusters with accumulations of amyloid precursor protein and amyloid precursor-like protein 2 immunoreactivity in brain regions damaged by thiamine deficiency. Am. J. Pathol. 149, 1063–1071.
Frederikse P.H., Garland D., Zigler J.S. Jr., and Piatigorsky J. (1996) Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J. Biol. Chem. 271, 10,169–10,174.
Misonou H., Morishima-Kawashima M., and Ihara Y. (2000) Oxidative stress induces intracellular accumulation of amyloid beta- protein (Abeta) in human neuroblastoma cells. Biochemistry 39, 6951–6959.
Olivieri G., Brack C., Muller-Spahn F., et al. (2000) Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J. Neurochem. 74, 231–236.
Gabuzda D., Busciglio J., Chen L.B., Matsudaira P., and Yankner B.A. (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 269, 13,623–13,628.
Webster M.T., Pearce B.R., Bowen D.M., and Francis P.T. (1998) The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J. Neural Transm 105, 839–853.
Cullen K.M. and Halliday G.M. (1995) Neurofibrillary tangles in chronic alcoholics. Neuropathol. Appl. Neurobiol. 21(4), 312–318.
Cheng B. and Mattson M.P. (1992) Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Exp. Neurol. 117, 114–123.
Blass J.P., Baker A.C., Ko L.W., and Black R.S. (1990) Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch. Neurol. 47, 864–869.
Gibson G.E. and Zhang H. (2000) Effects of ginkgo biloba (EGb761) on metabolism of reactive oxygen species in fibroblasts from Alzheimer’s disease patients and controls, in Advances in Ginkgo biloba Extract Research, vol 8, Ginkgo Biloba Extract (EGB 761) as a Neuroprotective Agent: From Basic Studies to Clinical Trials, Christen Y., ed. IPSEN Foundation Salal Editeur, Marseille, France.
Planel E., Miyasaka T., Launey T., et al. (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease. J. Neurosci. 24, 2401–2411.
Jauss M., Herholz K., Kracht L., et al. (2001) Frontotemporal dementia: clinical, neuroimaging, and molecular biological findings in 6 patients. Eur. Arch. Psychiatry Clin. Neurosci. 251, 225–231.
Calingasan N.Y. and Gibson G.E. (2000) Dietary restriction attenuates the neuronal loss, induction of heme oxygenase-1 and bloodbrain barrier breakdown induced by impaired oxidative metabolism. Brain Res. 885, 62–69.
Calingasan N.Y., Huang P.L., Chun H.S., Fabian A., and Gibson G.E. (2000) Vascular factors are critical in selective neuronal loss in an animal model of impaired oxidative metabolism. J. Neuropathol. Exp. Neurol. 59, 207–217.
Arivazhagan P., Ramanathan K., and Panneerselvam C. (2001) Effect of DL-alpha-lipoic acid on mitochondrial enzymes in aged rats. Chem. Biol. Interact. 138, 189–198.
Suh J.H., Shenvi S.V., Dixon B.M., Liu H., Jaiswal A.K., Liu R.M., et al. (2004) Decline in transcriptional activity of Nrf2 causes agerelated loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl. Acad. Sci. USA 101, 3381–3386.
Seaton T.A., Jenner P., and Marsden C.D. (1996) The isomers of thioctic acid alter C-deoxyglucose incorporation in rat basal ganglia. Biochem. Pharmacol. 51, 983–986.
Hager K., Marahrens A., Kenklies M., Riederer P., and Munch G. (2001) Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Arch. Gerontol. Geriatr. 32, 275–282.
Korotchkina L.G., Yang H., Tirosh O., Packer L., and Patel M.S. (2001) Protection by thiols of the mitochondrial complexes from 4-hydroxy-2-nonenal. Free Radical Biol. Med. 30, 992–999.
Andreassen O.A., Ferrante R.J., Huang H.M., et al. (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington’s disease. Ann. Neurol. 50, 112–117.
Blair P.V., Kobayashi R., Edwards H.M., 3rd, Shay N.F., Baker D.H., and Harris R.A. (1999) Dietary thiamin level influences levels of its diphosphate form and thiamin-dependent enzymic activities of rat liver. J. Nutr. 129, 641–648.
Mimori Y., Katsuoka H., and Nakamura S. (1996) Thiamine therapy in Alzheimer’s disease. Metab. Brain Dis. 11, 89–94.
Nolan K.A., Black R.S., Sheu K.F., Langberg J., and Blass J.P. (1991) A trial of thiamine in Alzheimer’s disease. Arch. Neurol. 48, 81–83.
Blass J.P. (2002) Metabolic enhancement in the treatment of Alzheimer Disease, in Research and Practice in Alzheimer’s Disease, Vellas B., Fitten L.J., Winblad B., Feldman H., Grundman M., and Giacobini E., eds., Springer-Verlag, New York, pp. 282–287.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gibson, G.E., Blass, J.P., Beal, M.F. et al. The α-ketoglutarate-dehydrogenase complex. Mol Neurobiol 31, 43–63 (2005). https://doi.org/10.1385/MN:31:1-3:043
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/MN:31:1-3:043